Elanco Animal Health Incorporated Q4 2025 Earnings Call Summary

Core Insights - The company achieved 9% organic constant currency revenue growth in Q4, marking 10 consecutive quarters of underlying growth driven by the U.S. farm and pet health sectors [1] Revenue Performance - Innovation revenue reached $892 million in 2025, outperforming expectations due to the rapid adoption of the 'Big Six' products, particularly Credelio Quattro and Zenrelia [1] - Credelio Quattro has become the fastest blockbuster in company history, gaining significant share in the $1.4 billion U.S. broad-spectrum parasiticide market through its unique four-ingredient differentiation [1] - Zenrelia is exceeding international expectations with double-digit market share in key regions like Brazil and Japan, driven by superior efficacy recognized by veterinarians [1] Sector Growth - U.S. Farm Animal growth of 17% was propelled by market leadership in cattle with Experior and Pradalex, despite historically small herd sizes [1] Strategic Initiatives - The 'no-regret' launch strategy, supported by expanded sales teams and DTC investment, is successfully converting innovation into market share gains across all major categories [1] - Operational efficiency and strong cash focus improved the net leverage ratio to 3.6x ahead of internal timelines, while the new Elanco Ascend initiative is set to drive further efficiencies starting in 2026 [1]